Back to the Top
The following message was posted to: PharmPK
Both ketoconazole 200 mg BID and 400 mg QD are often used in DDI
studies as potent CYP3A inhibitor. Could anyone please inform me if
there is any published literature documenting clinical trial data that
either directly or indirectly compared the inhibition potential/
capacity between the two dosing regimens? Please note that I'm not
interested in in silico prediction, or a theoretical discussion based
on in vitro in vivo extrapolation. I am looking for clinical trial
data in human subjects. Thanks in advance for your help.
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Inhibition of ketoconazole 200 mg BID vs 400 mg QD" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (email@example.com)